Advertisement
Journal of Biological Chemistry
Open access logo
Advanced searchSave search
Research Article| Volume 261, ISSUE 1, P328-333, January 05, 1986

Protein kinase activity of FSV (Fujinami sarcoma virus) P130gag-fps shows a strict specificity for tyrosine residues.

Open AccessPublished:January 05, 1986DOI:https://doi.org/10.1016/S0021-9258(17)42474-4
Protein kinase activity of FSV (Fujinami sarcoma virus) P130gag-fps shows a strict specificity for tyrosine residues.
Previous ArticleCocoa butter biosynthesis. Purification and characterization of a soluble sn-glycerol-3-phosphate acyltransferase from cocoa seeds.
Next ArticleImmunological quantitation of phospholipid/Ca2+-dependent protein kinase and its fragments. Tissue levels, subcellular distribution, and ontogenetic changes in brain and heart.
      This paper is only available as a PDF. To read, Please Download here.
      A number of oncogenic viruses encode transforming proteins with protein kinase activities apparently specific for tyrosine residues. Recent evidence has raised questions as to the substrate specificity of these kinases in general and the physiological relevance of tyrosine phosphorylation in particular. The P130gag-fps transforming protein of Fujinami sarcoma virus (FSV) is strongly phosphorylated at 2 tyrosine residues in FSV-transformed cells of which 1 (Tyr-1073) is also the major site of P130gag-fps intermolecular autophosphorylation in vitro. We have investigated the specificity of the protein kinase activity intrinsic to FSV P130gag-fps by using site-directed mutagenesis to change the codon for Tyr-1073 to those for the other commonly phosphorylated hydroxyamino acids, serine and threonine. This approach has some advantages over the use of synthetic peptides to define protein kinase recognition sites in that the protein containing the altered target site can be expressed in intact cells. In addition it allows higher order as well as primary structure of the enzyme recognition site to be considered. Neither serine nor threonine were phosphorylated when substituted for tyrosine at position 1073 of P130gag-fps indicating a stringent specificity for tyrosine as a substrate of the P130gag-fps protein kinase autophosphorylating activity. Consistent with the suggestion that tyrosine phosphorylation is of functional significance we find that these and other FSV Tyr-1073 mutants have depressed enzymatic and oncogenic capacities.

      REFERENCES

        • Cooper J.A.
        • Hunter T.
        Curr. Top. Microbiol. Immunol. 1983; 107: 125-161
        • Bryant D.L.
        • Parsons J.T.
        Mol. Cell Biol. 1984; 4: 862-866
        • Sugimoto Y.
        • Whitman M.
        • Cantley L.C.
        • Erikson R.L.
        Proc. Natl. Acad. Sci. U. S. A. 1984; 81: 2117-2121
        • Macara I.G.
        • Marinetti G.V.
        • Balduzzi P.C.
        Proc. Natl. Acad. Sci. U. S. A. 1984; 81: 2728-2732
        • Weinmaster G.
        • Hinze E.
        • Pawson T.
        J. Virol. 1983; 46: 29-41
        • Pawson T.
        • Guyden G.
        • Kung T.-H.
        • Radke K.
        • Gilmore T.
        • Martin G.S.
        Cell. 1980; 22: 767-775
        • Weinmaster G.
        • Zoller M.J.
        • Smith M.
        • Hinze E.
        • Pawson T.
        Cell. 1984; 37: 559-568
        • Mathey-Prevot B.
        • Shibuya M.
        • Samarut J.
        • Hanafusa H.
        J. Virol. 1984; 50: 325-334
        • Shibuya M.
        • Wang L.-H.
        • Hanafusa H.
        J. Virol. 1982; 42: 1007-1016
        • Zoller M.J.
        • Smith M.
        Methods Enzymol. 1983; 100: 468-501
        • Adams S.P.
        • Kovka K.S.
        • Wykes E.J.
        • Holder S.B.
        • Galluppi G.
        J. Am. Chem. Soc. 1983; 105: 661-663
        • Ingman-Baker J.
        • Hinze E.
        • Levy J.G.
        • Pawson T.
        J. Virol. 1984; 50: 572-578
        • Cooper J.A.
        • Esch F.S.
        • Taylor S.S.
        • Hunter T.
        J. Biol. Chem. 1984; 259: 7835-7841
        • Graham F.L.
        • Bacchetti S.
        • McKinnon R.
        • Stanners C.
        • Cordell B.
        • Goodman H.M.
        Baserga R. Croce C. Rpvera G. Introduction of Macromolecules into Viable Mammalian Cells. Alan R. Liss, New York1980: 3-25
        • Hunter T.
        J. Biol. Chem. 1982; 257: 4843-4848
        • Pike L.J.
        • Gallis B.
        • Casnellie J.E.
        • Bornstein P.
        • Krebs E.G.
        Proc. Natl. Acad. Sci. U. S. A. 1982; 79: 1443-1447
        • Wong T.W.
        • Goldberg A.R.
        J. Biol. Chem. 1983; 258: 1022-1025
        • Barker W.C.
        • Dayhoff M.O.
        Proc. Natl. Acad. Sci. U. S. A. 1982; 79: 2836-2839
        • Bolen D.W.
        • Stingelin J.
        • Bramson H.N.
        • Kaiser E.T.
        Biochemistry. 1980; 19: 1176-1182
        • Erneux C.
        • Cohen S.
        • Garbers D.L.
        J. Biol. Chem. 1983; 258: 4137-4142
        • Shibuya M.
        • Hanafusa H.
        Cell. 1982; 30: 787-795

      Article info

      Publication history

      Published online: January 05, 1986

      Identification

      DOI: https://doi.org/10.1016/S0021-9258(17)42474-4

      Copyright

      © 1986 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.

      User license

      Creative Commons Attribution (CC BY 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution (CC BY 4.0)

      Permitted

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article
      • Reuse portions or extracts from the article in other works
      • Sell or re-use for commercial purposes

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      ASBMB  ASBMB  ASBMB  ASBMB

      ISSN 0021-9258
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX